Mabspace Biosciences   Report issue

For profit Phase 1
Founded: Suzhou China (2011)

Organization Overview

First Clinical Trial
2018
NCT03463473
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Mabspace Biosciences | Mabspace Biosciences (Suzhou) Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (3)

msb0254 (1 trial)

msb2311 (2 trials)

tst001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 3